Eluminex Biosciences
Latest round
- Series B
Last raised
- Aug 2023
Total raised
- $100M
Investors
- 8
About Eluminex Biosciences
Founded in 2020 and based in Suzhou, China, Eluminex Biosciences Limited operates as a biotechnology company that researches and develops novel therapies for major eye diseases. It also established a branch office in San Francisco in 2021. The founder of the company, Jinzhong Zhang, was the pre-clinical vice president of Graybug Vision. Charles Semba, the Chief Medical Officer, worked at SARcode Bioscience, ForSight VISION5, and Gragybug Vision. In July 2021, Eluminex Biosciences acquired exclusive rights to the biosynthetic corneal technology and recombinant human type III collagen platform from Enabase, Inc. Eluminex Biosciences Limited has developed a full-length type III human collagen with a three-stranded helix structure through synthetic biology technology. The biosynthetic corneas made from type III human collagen can treat visual defects associated with corneal blindness. The company's biosynthetic corneas are registered for clinical trials as Class III medical devices. The pipelines offered by the company include EB-105, EB-110, EB-116, EB-301, and EB-401. In the ophthalmology field, it is developing multiple next-generation anti-VEGF multi-valent bio-macromolecules for the treatment of age- and diabetes-related retinal diseases and other retinal vascular diseases. In the field of ophthalmology, it is developing multiple next-generation anti-VEGF multi-target biomolecules for the treatment of age-related and diabetes-induced retinal diseases, with an initial program scheduled to enter the clinic in the United States in 2024.
Who invested in Eluminex Biosciences
8 investors across 3 rounds
See all investors in Eluminex Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Eluminex Biosciences
Who invested in Eluminex Biosciences?
Eluminex Biosciences has 8 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Eluminex Biosciences raised?
Eluminex Biosciences has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Eluminex Biosciences last raise money?
Eluminex Biosciences's most recent round on record is a Series B, in Aug 2023.
What does Eluminex Biosciences do?
Founded in 2020 and based in Suzhou, China, Eluminex Biosciences Limited operates as a biotechnology company that researches and develops novel therapies for major eye diseases.
Where is Eluminex Biosciences headquartered?
Eluminex Biosciences is headquartered in Suzhou, China.
Which VCs invest in companies like Eluminex Biosciences?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Eluminex Biosciences's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Eluminex Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.